In genetic and pharmacological studies, inhibiting SCD1 alters cellular lipid composition which disrupts plasma membrane fluidity leading to inhibiting of HCC cell invasion in vitro, which could serve as a biomarker for HCC aggressiveness (30, 83). Here, SCD is linked to hepatocellular carcinoma.